Bexorg, Inc.
Bexorg accelerates discovery of therapies for brain diseases by producing human brain datasets that predict target and therapeutic effects before clinical studies. It operates a proprietary whole-brain perfusion wet‑lab platform called BrainEx to maintain and manipulate intact mature human brains and generates high‑fidelity molecular and functional datasets that feed XO Digital, a machine‑learning/AI engine for predictive modeling. The company combines a B2B SaaS and services model, working with neuroscientists, CNS drug developers, and industry partners to integrate its platform into preclinical and clinical development programs. Bexorg stems from Yale research, has completed over 800 brain runs and multiple Nature‑published validations, and maintains an independent bioethics board while advancing in‑house neurodegeneration assets and collaborations.
Bexorg, Inc.
Bexorg accelerates discovery of therapies for brain diseases by producing human brain datasets that predict target and therapeutic effects before clinical studies. It operates a proprietary whole-brain perfusion wet‑lab platform called BrainEx to maintain and manipulate intact mature human brains and generates high‑fidelity molecular and functional datasets that feed XO Digital, a machine‑learning/AI engine for predictive modeling. The company combines a B2B SaaS and services model, working with neuroscientists, CNS drug developers, and industry partners to integrate its platform into preclinical and clinical development programs. Bexorg stems from Yale research, has completed over 800 brain runs and multiple Nature‑published validations, and maintains an independent bioethics board while advancing in‑house neurodegeneration assets and collaborations.